New drug combo aims to fight blood cancer with fewer nerve problems
NCT ID NCT02441686
Summary
This study tested a combination of three cancer drugs (lenalidomide, bortezomib, and dexamethasone) in 46 adults newly diagnosed with multiple myeloma, a cancer of plasma cells. The main goals were to see how well the treatment worked to control the cancer and to check if giving one drug as an injection under the skin instead of into a vein would cause less nerve damage, a common and painful side effect. Researchers measured how many patients responded to treatment and tracked side effects over time.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Colorado Blood Cancer Institute
Denver, Colorado, 80218, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Eastern Maine Medical Center
Brewer, Maine, 04412, United States
-
Hematology Oncology of Northern New Jersey
Morristown, New Jersey, 07962, United States
-
Massachusetts General Hosptial
Boston, Massachusetts, 02114, United States
-
Virgina Piper Cancer Institute
Minneapolis, Minnesota, 55407, United States
-
Virginia Piper Cancer Institute
Coon Rapids, Minnesota, 55433, United States
Conditions
Explore the condition pages connected to this study.